{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:13:46Z","timestamp":1761675226076},"reference-count":115,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.addr.2005.01.010","type":"journal-article","created":{"date-parts":[[2005,4,19]],"date-time":"2005-04-19T13:53:33Z","timestamp":1113918813000},"page":"1247-1265","source":"Crossref","is-referenced-by-count":43,"title":["Particulate delivery systems for biodefense subunit vaccines"],"prefix":"10.1016","volume":"57","author":[{"given":"Vincent W.","family":"Bramwell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim E.","family":"Eyles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Oya Alpar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2005.01.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-1656(99)00107-8","article-title":"Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines","volume":"73","author":"Liljeqvist","year":"1999","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.addr.2005.01.010_bib2","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/S0264-410X(03)00164-6","article-title":"Third meeting on novel adjuvants currently in or close to clinical testing","volume":"21","author":"Engers","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib3","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0264-410X(95)00011-O","article-title":"Adjuvants for human vaccines\u2014current status, problems and future prospects","volume":"13","author":"Gupta","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","article-title":"Aluminum compounds as vaccine adjuvants","volume":"32","author":"Gupta","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2005.01.010_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0264-410X(96)00183-1","article-title":"Adjuvants\u2014a classification and review of their modes of action","volume":"15","author":"Cox","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib6","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/brain\/124.9.1821","article-title":"Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle","volume":"124","author":"Gherardi","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.addr.2005.01.010_bib7","first-page":"162","article-title":"Lessons from macrophagic myofasciitis: Towards definition of a vaccine adjuvant-related syndrome","volume":"159","author":"Gherardi","year":"2003","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.addr.2005.01.010_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2567.2002.01382.x","article-title":"Lung dendritic cells are primed by inhaled particulate antigens, and retain MHC class II\/antigenic peptide complexes in hilar lymph nodes for a prolonged period of time","volume":"105","author":"Vu","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2005.01.010_bib9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jbm.10019","article-title":"Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo","volume":"60","author":"Newman","year":"2002","journal-title":"J. Biomed. Materi. Res."},{"key":"10.1016\/j.addr.2005.01.010_bib10","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.4049\/jimmunol.156.8.2809","article-title":"Analysis of MHC class II presentation of particulate antigens of B lymphocytes","volume":"156","author":"Vidard","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2005.01.010_bib11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0264-410X(02)00531-5","article-title":"Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro","volume":"21","author":"Sun","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib12","first-page":"257","article-title":"Design and delivery of non-parenteral vaccines","volume":"23","author":"Nugent","year":"1998","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.addr.2005.01.010_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0169-409X(98)00012-X","article-title":"Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines","volume":"32","author":"O'Hagan","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2005.01.010_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/02652049609026050","article-title":"Properties of multiphase microspheres of poly(dl-lactic acid) or poly(dl-lactic-co-glycolic acid) produced by mechanical agitation, sonication, or potentiometric dispersion","volume":"13","author":"Odonnell","year":"1996","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2005.01.010_bib15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0264-410X(02)00521-2","article-title":"Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro","volume":"21","author":"Audran","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0165-2478(97)00107-7","article-title":"Visualization of peptides derived from liposome-encapsulated proteins in the trans-golgi area of macrophages","volume":"59","author":"Rao","year":"1997","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.addr.2005.01.010_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis\u2014etiologic agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2005.01.010_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s100960050219","article-title":"Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections","volume":"18","author":"Smego","year":"1999","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.addr.2005.01.010_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1365-2672.2001.01497.x","article-title":"Plague vaccine research and development","volume":"91","author":"Williamson","year":"2001","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.addr.2005.01.010_bib20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0264-410X(95)00090-N","article-title":"A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model","volume":"13","author":"Russell","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4049\/jimmunol.68.2.131","article-title":"Studies on immunization against plague: I. The isolation and characterization of the soluble antigen of Pasteurella pestis","volume":"68","author":"Baker","year":"1952","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2005.01.010_bib22","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1128\/jb.171.10.5646-5653.1989","article-title":"Molecular analysis of lcrGVH, the V antigen operon of Yersinia pestis","volume":"171","author":"Price","year":"1989","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2005.01.010_bib23","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1128\/jb.173.8.2649-2657.1991","article-title":"The Yersinia pestis V antigen is a regulatory protein necessary for Ca2(+)-dependent growth and maximal expression of low-Ca2+ response virulence genes","volume":"173","author":"Price","year":"1991","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2005.01.010_bib24","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1128\/jb.177.20.5997-6000.1995","article-title":"Transcriptional analysis of the Yersinia pestis pH 6 antigen gene","volume":"177","author":"Price","year":"1995","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2005.01.010_bib25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1128\/IAI.51.2.445-454.1986","article-title":"Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins","volume":"51","author":"Straley","year":"1986","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2005.01.010_bib26","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1128\/IAI.63.8.2854-2858.1995","article-title":"Active immunization with recombinant V-antigen from Yersinia pestis protects mice against plague","volume":"63","author":"Leary","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2005.01.010_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/bmb\/62.1.163","article-title":"Vaccines against dangerous pathogens","volume":"62","author":"Williamson","year":"2002","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.addr.2005.01.010_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0264-410X(00)00159-6","article-title":"A single dose sub-unit vaccine protects against pneumonic plague","volume":"19","author":"Williamson","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(96)00303-9","article-title":"A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague","volume":"15","author":"Williamson","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-695X.1995.tb00196.x","article-title":"A new improved subunit vaccine for plague\u2014the basis of protection","volume":"12","author":"Williamson","year":"1995","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.addr.2005.01.010_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","article-title":"Biodegradation and biocompatibility of PLA and PLGA microspheres","volume":"28","author":"Anderson","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2005.01.010_bib32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00063030-199912060-00004","article-title":"Prospects for the development of new vaccine adjuvants","volume":"12","author":"Cox","year":"1999","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2005.01.010_bib33","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0264-410X(96)00151-X","article-title":"Local and systemic immune response to a microencapsulated sub-unit vaccine for plague","volume":"14","author":"Williamson","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-3659(99)00197-2","article-title":"Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits","volume":"63","author":"Eyles","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2005.01.010_bib35","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S0264-410X(98)00089-9","article-title":"Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines","volume":"16","author":"Eyles","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib36","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/S0264-410X(00)00019-0","article-title":"Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses","volume":"18","author":"Baca-Estrada","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0264-410X(97)00305-8","article-title":"Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis","volume":"16","author":"Reddin","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib38","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nbt1184-979","article-title":"Dehydration\u2013rehydration vesicles\u2014a simple method for high-yield drug entrapment in liposomes","volume":"2","author":"Kirby","year":"1984","journal-title":"Biotechnology"},{"key":"10.1016\/j.addr.2005.01.010_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(04)16769-X","article-title":"Clinical predictors of bioterrorism-related inhalational anthrax","volume":"364","author":"Kyriacou","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2005.01.010_bib40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2672.2001.01498.x","article-title":"The development of new vaccines against Bacillus anthracis","volume":"91","author":"Baillie","year":"2001","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.addr.2005.01.010_bib41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0264-410X(97)00268-5","article-title":"Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers","volume":"16","author":"McBride","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8561(03)00093-6","article-title":"Anthrax vaccine: a review","volume":"23","author":"Grabenstein","year":"2003","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.addr.2005.01.010_bib43","first-page":"349","article-title":"Protective antigen present in cell-free culture filtrates","volume":"27","author":"Gladstone","year":"1946","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.addr.2005.01.010_bib44","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2005.01.010_bib45","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"key":"10.1016\/j.addr.2005.01.010_bib46","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/IAI.72.6.3471-3477.2004","article-title":"Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine","volume":"72","author":"Marcus","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2005.01.010_bib47","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/IAI.70.4.2022-2028.2002","article-title":"Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2005.01.010_bib48","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.1834478100","article-title":"A dually active anthrax vaccine that confers protection against both bacilli and toxins","volume":"100","author":"Rhie","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2005.01.010_bib49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1128\/MMBR.48.3.199-221.1984","article-title":"Bacterial toxins: cellular mechanisms of action","volume":"48","author":"Middlebrook","year":"1984","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.addr.2005.01.010_bib50","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0264-410X(98)00175-3","article-title":"Identifying the principal protective antigenic determinants of type A botulinum neurotoxin","volume":"16","author":"Bavari","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","article-title":"Identification of the major steps in botulinum toxin action","volume":"44","author":"Simpson","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.addr.2005.01.010_bib52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4049\/jimmunol.90.5.697","article-title":"Studies on immunity to toxins of Clostridium botulinum: IX. Immunologic response of man to purified pentavalent ABCDE botulinum toxiod","volume":"90","author":"Fiock","year":"1963","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2005.01.010_bib53","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1128\/JCM.26.11.2351-2356.1988","article-title":"Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay","volume":"26","author":"Siegel","year":"1988","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2005.01.010_bib54","unstructured":"R.J. Ellis, Immunobiologic agents and drugs available from the centers for disease control: Descriptions, recommendations, adverse reactions, and serologic response, Atlanta, GA: Centers for Disease Control, Public Health Service, US Department of Health and Human Services; 3rd ed., 1982 (Report)."},{"key":"10.1016\/j.addr.2005.01.010_bib55","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/JCM.27.8.1906-1908.1989","article-title":"Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid","volume":"27","author":"Siegel","year":"1989","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2005.01.010_bib56","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/S0264-410X(03)00460-2","article-title":"Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers","volume":"21","author":"Edelman","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib57","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0041-0101(95)00072-T","article-title":"Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen","volume":"33","author":"LaPenotiere","year":"1995","journal-title":"Toxicon"},{"key":"10.1016\/j.addr.2005.01.010_bib58","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/IAI.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2005.01.010_bib59","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/S0264-410X(96)00094-1","article-title":"Mapping of protective and cross-reactive domains of the type a neurotoxin of Clostridium botulinum","volume":"14","author":"Dertzbaugh","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib60","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"key":"10.1016\/j.addr.2005.01.010_bib61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/prep.2000.1256","article-title":"Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype a, expressed in the methylotrophic yeast Pichia pastoris","volume":"19","author":"Potter","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.addr.2005.01.010_bib62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/prep.2000.1200","article-title":"Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris","volume":"18","author":"Byrne","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.addr.2005.01.010_bib63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1128\/CDLI.11.3.496-502.2004","article-title":"Vaccination with recombinant whole heavy chain fragments of clostridium botulinum type C and D neurotoxins","volume":"11","author":"Arimitsu","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.addr.2005.01.010_bib64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7589\/0090-3558-36.3.489","article-title":"Efficacy of a type C botulism vaccine in green-winged teal","volume":"36","author":"Rocke","year":"2000","journal-title":"J. Wildl. Dis."},{"key":"10.1016\/j.addr.2005.01.010_bib65","doi-asserted-by":"crossref","first-page":"M649","DOI":"10.1097\/00002480-199609000-00068","article-title":"Microencapsulated vaccines to provide prolonged immunity with a single administration","volume":"42","author":"Whalen","year":"1996","journal-title":"ASAIO J."},{"key":"10.1016\/j.addr.2005.01.010_bib66","article-title":"Use of poly-l-lactide microspheres for the delivery of a Clostridium botulinum type F subunit vaccine","author":"Holley","year":"2001"},{"key":"10.1016\/j.addr.2005.01.010_bib67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1081\/CLT-120030945","article-title":"Ricin: mechanism of toxicity, clinical manifestations, and vaccine development. A review","volume":"42","author":"Doan","year":"2004","journal-title":"J. Toxicol., Clin. Toxicol."},{"key":"10.1016\/j.addr.2005.01.010_bib68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00139709-200322010-00006","article-title":"Ricin. Mechanisms of cytotoxicity","volume":"22","author":"Lord","year":"2003","journal-title":"Toxic. Rev."},{"key":"10.1016\/j.addr.2005.01.010_bib69","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2004.01.024","article-title":"Insertional mutagenesis of ricin a chain: a novel route to an anti-ricin vaccine","volume":"22","author":"Marsden","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/protein\/gzh043","article-title":"Finding a new vaccine in the ricin protein fold","volume":"17","author":"Olson","year":"2004","journal-title":"Protein Eng. Des., Sel."},{"key":"10.1016\/j.addr.2005.01.010_bib71","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/S0264-410X(02)00312-2","article-title":"A novel recombinant vaccine which protects mice against ricin intoxication","volume":"20","author":"Smallshaw","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib72","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0264-410X(01)00484-4","article-title":"Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge","volume":"20","author":"Kende","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib73","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0264-410X(96)00063-1","article-title":"Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres","volume":"14","author":"Yan","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib74","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0264-410X(94)00026-J","article-title":"Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers","volume":"13","author":"Yan","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib75","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0264-410X(97)80007-2","article-title":"Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations","volume":"16","author":"Griffiths","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib76","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/S0264-410X(99)00054-7","article-title":"Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation","volume":"17","author":"Griffiths","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0166-3542(02)00196-1","article-title":"Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections","volume":"57","author":"Baker","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2005.01.010_bib78","series-title":"Smallpox and Its Eradication","isbn-type":"print","author":"Fenner","year":"1988","ISBN":"http:\/\/id.crossref.org\/isbn\/9241561106"},{"key":"10.1016\/j.addr.2005.01.010_bib79","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199808203390811","article-title":"Poxvirus dilemmas\u2014monkeypox, smallpox, and biologic terrorism","volume":"339","author":"Breman","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2005.01.010_bib80","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1086\/381976","article-title":"Looking back at smallpox","volume":"38","author":"Bray","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2005.01.010_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0166-3542(02)00199-7","article-title":"A review of compounds exhibiting anti-orthopoxvirus activity in animal models","volume":"57","author":"Smee","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2005.01.010_bib82","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0889-8561(03)00096-1","article-title":"Smallpox vaccine: problems and prospects","volume":"23","author":"Poland","year":"2003","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.addr.2005.01.010_bib83","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/095632020101200105","article-title":"Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir","volume":"12","author":"Smee","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.addr.2005.01.010_bib85","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1128\/JVI.78.13.7052-7060.2004","article-title":"Protection against lethal vaccinia virus challenge in hla-a2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses","volume":"78","author":"Snyder","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2005.01.010_bib86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0166-3542(02)00200-0","article-title":"Defense against filoviruses used as biological weapons","volume":"57","author":"Bray","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2005.01.010_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(02)00005-0","article-title":"Experimental therapy of filovirus infections","volume":"54","author":"Bray","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2005.01.010_bib88","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/1099800403252603","article-title":"A current review of ebola virus: pathogenesis, clinical presentation, and diagnostic assessment","volume":"4","author":"Casillas","year":"2003","journal-title":"Biol. Res. Nurs."},{"key":"10.1016\/j.addr.2005.01.010_bib89","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/515386","article-title":"A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever","volume":"178","author":"Bray","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2005.01.010_bib90","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.addr.2005.01.010_bib91","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0264-410X(01)00353-X","article-title":"Marburg virus vaccines: comparing classical and new approaches","volume":"20","author":"Hevey","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib92","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1016\/j.vaccine.2004.01.063","article-title":"Marburg virus-like particles protect guinea pigs from lethal marburg virus infection","volume":"22","author":"Warfield","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib93","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2005.01.010_bib94","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/S0264-410X(99)00170-X","article-title":"Cytotoxic T lymphocytes to ebola zaire virus are induced in mice by immunization with liposomes containing lipid A","volume":"17","author":"Rao","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib95","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1128\/JVI.76.18.9176-9185.2002","article-title":"Induction of immune responses in mice and monkeys to ebola virus after immunization with liposome-encapsulated irradiated ebola virus: protection in mice requires CD4+ T cells","volume":"76","author":"Rao","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2005.01.010_bib96","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0928-0987(01)00175-0","article-title":"Oral vaccination in man using antigens in particles: current status","volume":"14","author":"Brayden","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2005.01.010_bib97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2500\/108854101778148773","article-title":"Alternative routes of immunization for prevention of infectious diseases: a new paradigm for the 21st century","volume":"22","author":"Bellanti","year":"2001","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.addr.2005.01.010_bib98","first-page":"487","article-title":"Particle uptake and translocation across epithelial membranes","volume":"189","author":"Thomas","year":"1996","journal-title":"J. Anat."},{"key":"10.1016\/j.addr.2005.01.010_bib99","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.2042-7158.1994.tb03876.x","article-title":"Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system","volume":"46","author":"Critchley","year":"1994","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2005.01.010_bib100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0168-3659(00)00330-8","article-title":"A novel bioadhesive intranasal delivery system for inactivated influenza vaccines","volume":"70","author":"Singh","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2005.01.010_bib101","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.2042-7158.1995.tb06714.x","article-title":"The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat","volume":"47","author":"Eyles","year":"1995","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2005.01.010_bib102","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.2042-7158.1989.tb06429.x","article-title":"The transport of microspheres from the gastro-intestinal tract to inflammatory air pouches in the rat","volume":"41","author":"Alpar","year":"1989","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2005.01.010_bib103","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1461-5347(98)00075-3","article-title":"Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines","volume":"1","author":"Brayden","year":"1998","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.addr.2005.01.010_bib104","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1016\/S0264-410X(01)00220-1","article-title":"Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration","volume":"19","author":"Eyles","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/biol.1999.0191","article-title":"Composition of acellular pertussis and combination vaccines: a general review","volume":"27","author":"Jadhav","year":"1999","journal-title":"Biologicals"},{"key":"10.1016\/j.addr.2005.01.010_bib106","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.285.21.2763","article-title":"Tularemia as a biological weapon: medical and public health management","volume":"285","author":"Dennis","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2005.01.010_bib107","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0264-410X(91)90237-Z","article-title":"Anthrax vaccines: past, present and future","volume":"9","author":"Turnbull","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib108","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2005.01.010_bib109","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","article-title":"In vitro correlate of immunity in an animal model of inhalational anthrax","volume":"87","author":"Pitt","year":"1999","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.addr.2005.01.010_bib110","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0264-410X(97)00249-1","article-title":"Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse","volume":"16","author":"Eyles","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib111","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon: medical and public health management. Working group on civilian biodefense","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2005.01.010_bib112","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0169-409X(01)00166-1","article-title":"Intranasal vaccination against plague, tetanus and diphtheria","volume":"51","author":"Alpar","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2005.01.010_bib113","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/S0264-410X(02)00396-1","article-title":"Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-[gamma] or IL-4, but not IL-6","volume":"20","author":"Griffin","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2005.01.010_bib114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-2427(98)00089-0","article-title":"Cytokine adjuvants: lessons from the past-guidelines for the future?","volume":"63","author":"Hughes","year":"1998","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.addr.2005.01.010_bib115","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0264-410X(97)80005-9","article-title":"Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-[gamma]: effect of dose and formulation","volume":"16","author":"Griffin","year":"1998","journal-title":"Vaccine"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X05000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X05000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:32:52Z","timestamp":1683073972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X05000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":115,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0169409X05000438"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2005.01.010","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}